Propel Bio Management, LLC Delcath Systems, Inc. Transaction History
Propel Bio Management, LLC
- $86.1 Billion
- Q1 2025
A detailed history of Propel Bio Management, LLC transactions in Delcath Systems, Inc. stock. As of the latest transaction made, Propel Bio Management, LLC holds 177,600 shares of DCTH stock, worth $1.78 Million. This represents 2.63% of its overall portfolio holdings.
Number of Shares
177,600
Previous 17,000
944.71%
Holding current value
$1.78 Million
Previous $205 Million
1004.58%
% of portfolio
2.63%
Previous 0.2%
Shares
2 transactions
Others Institutions Holding DCTH
# of Institutions
109Shares Held
12.7MCall Options Held
79KPut Options Held
53.3K-
Vanguard Group Inc Valley Forge, PA1.61MShares$16.1 Million0.0% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY813KShares$8.14 Million0.26% of portfolio
-
Vivo Capital, LLC Palo Alto, CA750KShares$7.51 Million2.59% of portfolio
-
Geode Capital Management, LLC Boston, MA703KShares$7.04 Million0.0% of portfolio
-
Exodus Point Capital Management, LP New York, NY699KShares$7 Million0.09% of portfolio
About DELCATH SYSTEMS, INC.
- Ticker DCTH
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Devices
- Shares Outstandng 8,597,680
- Market Cap $86.1M
- Description
- Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling syste...